LHyal (Leech Hyaluronidase)
Hyperactive Hirudo medicinalis hyaluronate hydrolase used for HA oligosaccharide industrial production — Liao 2023 yeast-surface-display recombinant biocatalyst.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- LHyal (Leech Hyaluronidase)50 kDa
- Leech Thrombospondin-Like Protein50 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
Clinical translation limit
LHyal's enzymatic activity in industrial HA oligosaccharide production does NOT establish clinical efficacy as a therapeutic agent. No FDA-approved LHyal derivative exists.
Molecular Profile
- Category
- ECM Enzyme
- Evidence tier
- Preclinical
- Molecular weight
- 50,000 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2023 · Liao L et al.
Biological Targets
- → hyaluronic acid (extracellular matrix); produces size-specific HA oligosaccharides
Key Citations
- Liao L et al. (2023), Eng Microbiol · PMID 39628912